Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preservative-Free Tafluprost vs Timolol in Glaucoma and Ocular Hypertension
NCT01026831Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2010
- Primary completion
- Sep 2010
- Modality
- Orthosteric Ligands
01
Overview
Phase 3, randomised, double-blind trial of tafluprost in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Merck & Co. Primary endpoint: Mean Intraocular Pressure (IOP) Change From Baseline at 12 weeks. Started Jan 2010; status: completed.
02
Drugs
tafluprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT01026831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01026831.